Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Updated Sep 19, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 2.4% to $239.56 as of September 19, 2026, a modest decline from the prior close of $245.51. BestStocks flagged the session as a major change for ALNY. The move is tied to price move down. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
ALNY fell 2.4% to $239.56
Alnylam Pharmaceuticals, Inc. (ALNY) moved -2.81% from $246.49 to $239.56 on 2026-09-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on elevated volume (2.2x the 5-day average), suggesting institutional activity, though the underlying driver remains unclear. Monitor ALNY earnings results on 2026-10-29 to see whether the company beats or misses the $1.79 EPS consensus estimate.
This summary describes the catalyst and move as first detected on Sep 18, 2026, 4:45 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
1.7×
Above Avg
Vs peers
—
No comparable peers
Market cap
$32.1B
NASDAQ Global Select
Analyst target
$347
+45.0% vs price
Price chart
Aug 19 – Sep 18
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Negative session, down 2.4%. Wall Street's consensus price target sits at $347.33, implying +45.0% upside from $239.56. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (51/100). With earnings roughly 40 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $239.56, down $5.95 (-2.42%) from the previous close of $245.51. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $229.30 and $267.40, and it currently sits about 27% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $347.33, 45.0% above the recent $239.56. Over the past 90 days analysts logged 1 upgrade, 22 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
▲ The bullish case
+Wall Street's consensus price target of $347.33 implies +45.0% upside from $239.56.
+The Street's most bullish target is $455.00 (+89.9%).
+1 analyst upgrade in the past 90 days, most recently Raymond James to Strong Buy (2026-08-03).
+Positive price momentum.
▼ The bearish case
−Material negative event.
−Negative session, down 2.4%.
−Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Alnylam Pharmaceuticals, Inc. (ALNY) moved -3.53% from $246.99 to $238.27 on September 15, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the decline was not driven by unusual trading activity.
Material / Earnings2026-09-10-4.1%
Alnylam Pharmaceuticals, Inc. (ALNY) moved -3.57% from $256.68 to $247.51 on 2026-09-10. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-09-04+0.6%
Alnylam Pharmaceuticals, Inc. (ALNY) moved +3.13% from $258.02 to $266.11 on 2026-09-04. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Alnylam Pharmaceuticals surged +9.18% to $268.71 following positive clinical data presentations at the European Society of Cardiology (ESC) Congress 2026, according to the web_catalyst. The company showcased expanded HELIOS-B and Amvuttra data demonstrating strength of its RNAi-powered TTR silencing across ATTR-CM patient populations, reinforcing analyst outlooks for pipeline candidates nucresiran and TRITON-CM and easing prior investor concerns from earlier summer turbulence. Volume of 947,294 shares traded 1.66x normal levels for this point in the session.
Alnylam Pharmaceuticals rose 2.52% to $246.76 following positive clinical data presentations at the European Society of Cardiology (ESC) Congress 2026, featuring new efficacy data for Amvuttra (vutrisiran) across ATTR amyloidosis patient populations and cardiovascular pipeline updates including zilebesiran for hypertension (web_catalyst via ESC Congress 2026 presentations). Volume was below average at 0.62x expected for this time of day.
Material / Earnings2026-08-31+1.5%
Alnylam Pharmaceuticals, Inc. (ALNY) moved +2.91% from $233.88 to $240.69 on 2026-08-31. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-08-28+0.2%
Alnylam Pharmaceuticals, Inc. (ALNY) moved +5.63% from $224.47 to $237.10 on 2026-08-28. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x.
Material / Earnings2026-08-21+3.0%
Alnylam Pharmaceuticals, Inc. (ALNY) moved +3.21% from $228.88 to $236.22 on 2026-08-21. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x.
In-depth ALNY event analyses
Permanent, dated analyses of ALNY's most significant sessions.
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY fell 2.4% to $239.56. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ALNY stock fall?
ALNY lost 2.42% ($5.95) versus the prior close of $245.51, last trading at $239.56 on 1.7× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2026-10-29 — about 40 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $347.33, about 45.0% above the current $239.56. Over the past 90 days, analysts recorded 1 upgrade, 22 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
